Neoplasm
Conditions
Brief summary
P276-00 is a molecule derived from Rohitukine, which through pre clinical assays was identified as a selective Cdk4-D1 and Cdk1-B inhibitor.The inhibition of these Cdks causes cell cycle arrest between the G1-S transition thus blocking the cell cycle events at an early stage of development. It therefore has the potential for being efficacious with lesser side effects.
Interventions
DRUGP276-00
Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
Sponsors
Piramal Enterprises Limited
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients must have histologically and/ or cytologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. 2. Patients of either sex, of all races and ethnic groups, and \> 18 years of age. 3. ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2 . 4. Patients with life expectancy of at least 4 months. 5. Patients must have normal organ and marrow function as defined below: * Hemoglobin ≥10 gm/dL * absolute neutrophil count ≥ 1,500/mL * platelets ≥ 100,000/mL * total bilirubin within normal institutional limits * AST/ALT ≤ 2.5 X institutional upper limit of normal (ULN) * creatinine within 1.5 times the upper normal institutional limits 6. The effects of P276-00 on the developing human foetus are unknown. For this reason women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of the study during the duration of study participation and for at least 4 weeks after withdrawal from the study. 7. Women who are nursing should not be included into the study 8. Concomitant medications for diabetes, hypertension, pain relief and any other co-existing conditions, except cancer, are permitted when the patient is on study medication. There should be no change in the dosage of these medications in the 2 weeks prior to day 1 of cycle 1, with the exception of dosages for pain relief medication. Changes in the dose of anti-emetics and diuretics may be made provided they will not interfere with probable adverse effects of investigational product. 9. Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study (date of consent); or patients who have not recovered from adverse events (except grade 1 toxicities) due to agents administered more than 4 weeks earlier. 2. Patients having received any other investigational agents within 4 weeks prior to the date of consent and patients who have not recovered completely from the side effects of the earlier investigational agent. 3. Patients with known brain metastases should be excluded from this clinical trial. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to P276-00. 5. Patients having history of myocardial infarction or uncontrolled cardiac dysfunction during the previous 6 months. 6. Patients having diarrhea requiring anti-diarrheal therapy. 7. Patients having coagulopathy requiring anticoagulation. 8. Patients with uncontrolled but stable intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 9. Women who are pregnant or nursing. P276-00 may have the potential for teratogenic or abortifacient effects. Since there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with P276-00, breastfeeding should be discontinued if the mother is to be treated with P276-00. 10. Patients with immune deficiency are at increased risk of lethal infections when treated with marrow-suppressive therapy. Therefore, HIV-positive patients are excluded from the study. 11. Patients requiring the use of concomitant medications that prolong the QT/QTc interval and/or are known to cause Torsades de Pointes (TdP)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety assessment by Laboratory investigations (Hematology,Biochemistry, urinalysis), ECG, Holter monitoring,Physical examination | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Tumor measurements,Pharmacokinetics, MALDI- TOF to study plasma peptide pattern | 2 years |
Countries
India
Outcome results
None listed